Topic Listing for ONCOTHYREON INC

Accounting Certain Hybrid Financial Instruments Accounting Changes
Accounting Estimates Accounting Non Refundable Advance Payments Goods Services Received
Accounting Non-refundable Advance Payments Goods Services Received Future Accounting Tax Considerations
Accounting Uncertainty Income Taxes Accounts Receivable Government Grant Payable Accrued Liabilities
Accumulated Other Comprehensive Income Loss Accumulated Other Comprehensive Loss
Acquisition Prolx Pharmaceuticals Corporation Additional Provisions
Administration Administrator
Agreement Agreement Former Chief Executive Officer
Amendment Termination Annual Report
Annual Review Process Approval Related Party Transactions
Approve Amendment Restricted Share Unit Plan Assurance Granted Regulatory Approval Product Candidates
Audit Committee Audit Committee Report 2007
Audit Committee Report 2008 Audit Fees
Audit-related Fees Authorized Shares
Available Information Available-for-sale
Base Salary Basis Consolidation
Basis Presentation Because Not Expect Pay Dividends Common Stock Stockholders
Bellevue Bellevue Washington
Beneficial Ownership Reporting Compliance Benefits
Bglp40 Liposome Vaccine Product Candidate Board
Board Directors Board Directors Committee Meetings
Business Business Combinations
Business Subject Increasingly Complex Environmental Legislation Increased Costs Canada
Canadian Foreign Regulation Capital Disclosures
Capital Lease Obligations Capital Leases
Cash Equivalents Cash Equivalents Short Term Investments Working Capital
Cash Flows Financing Activities Cash Flows Investing Activities
Cash Flows Operating Activities Certain Relationships Related Transactions
Change Control Change Fair Value Warrant Liability
Change Fair Value Warrants Change Reporting Entity
Changes Financial Accounting Standards Related Share-based Payments Expected Changes Internal Control Over Financial Reporting
Chief Executive Officer Class Preferred Stock
Clinical Results Status Code
Code Conduct Collaborative Arrangements
Committees Board Directors Common Stock
Common Stock Become Ineligible Listing Nasdaq Global Market Common Stock Become Ineligible Listing Nasdaq Market Materially
Communications Board Directors Comparison Cumulative Total Return
Compensation Committee Compensation Committee Interlocks Insider Participation
Compensation Committee Report Compensation Directors
Compensation Philosophy Objectives Competition
Competitive Market Review 2007 Competitive Market Review 2008
Continuing Threat Terrorist Attacks United States Current Concern Contractual Obligations Contingencies
Conversion Restricted Share Units Corporate Controller Secretary
Corporate Governance Guidelines Corporation
Counting Votes Credit Risk
Critical Accounting Policies Significant Judgments Estimates Currently Rely Party Manufacturers Supply Product Candidates Delay
Deferred Payments Definitions
Delivered E-mail Dependent Collaborative Relationship Merck Kgaa Develop Commercialize Lead
Depreciation Derivative Financial Instruments
Description Property Determination Useful Life Intangible Assets
Determinations Regarding Director Independence Determining Variability Considered Applying Acg-15
Director Director Compensation
Director Continuing Office Until 2011 Annual Meeting Stockholders Directors Continuing Office Until 2009 Annual Meeting Stockholders
Directors Continuing Office Until 2010 Annual Meeting Stockholders Directors Executive Officers Corporate Governance
Discretion Dividends
Documents Incorporated Reference Earnings Loss Per Share
Earnings Per Share Edward Taylor
Effect Change Control Effective Date
Effective Date Term Plan Effects Alteration Share Capital
Embedded Derivatives Employee
Employee Benefit Plan Employee Benefit Plans
Employee Future Benefits Employees
Employment Agreements Offer Letters Equity Compensation Plan Information 2007
Equity Compensation Plan Information 2008 Equity Placements
Equity-based Incentives Evaluation Disclosure Controls Procedures
Even Regulatory Approval Received Product Candidates Later Discovery Exact Name Registrant Specified Charter
Exact Name Registrant Specified Charter Including Zip Code Executive Officers
Expand Business Through Acquisition Companies Businesses In-licensing Product Expenses
Face Potential Product Liability Exposure Successful Claims Brought Face Substantial Competition Result Others Discovering Developing Commercializing
Factors Affect Future Results Fail Establish Maintain Proper Effective Internal Controls Ability
Fail Obtain Additional Financing Needed Unable Complete Development Failure Delay Commencing Completing Clinical Trials Product Candidates
Failure Enroll Patients Clinical Trials Cause Delays Developing Failure Obtain Regulatory Approval Foreign Jurisdictions Prevent Marketing
Fair Market Value Fair Value Measurements
Fair Value Option Financial Assets Liabilities Fast Track Designation Priority Review
Fees Billed Deloitte Touche Llp 2007 Fees Billed Deloitte Touche Llp 2008
Figure Financial Instruments
Financial Instruments Disclosures Presentations Financial Risk
Foreign Currency Exchange Risk Foreign Currency Translation
Foreign Exchange Foreign Exchange Risk
Foreign Governments Often Impose Strict Price Controls Adversely Form 10-k
Future Sales Shares Existing Stockholders Cause Stock Price Gaap Hierarchy
Gary Christianson General
General Administrative Going Concern
Goodwill Goodwill Impairment
Governing Law Government Grants
Grant Grant Date
Grant Period Grants
Grants Plan-based Awards Guarantees
Guarantees Indemnification Held 2008
Held 2009 Held-for-trading
Held-to-maturity History Net Losses Anticipate Additional Never Become Profitable
Householding Proxy Materials Identification Period
In-process Research Development Income Tax Recovery
Income Taxes Indebtedness Directors Officers
Index Index Consolidated Financial Statements
Information Concerning Nominees Election Class Directors Inherent Limitation Effectiveness Internal Controls
Insider Interest Rate Risk
Interest Rate Sensitivity Inventories
Inventory Investment Other Loss Income
Investments Issue Rsus
Issue Shares Preferred Stock Adversely Affect Rights Stockholder License Agreements
Limitations Liquidity Capital Resources
Long-lived Assets Lose Key Personnel Unable Attract Retain Highly-qualified Cost-effective
Lynn Kirkpatrick Managements Annual Report Internal Control Over Financial Reporting
Manufacturing Market Information Common Stock
Market Opportunity Targeted Small Molecules Marketing Business Development
Nda Bla Approval Process Near-term Success Highly Dependent Lead Product Candidate Stimuvax
Nominating Governance Committee Nominees Class Directors Election 2008 Annual Meeting Stockholders
Nominees Class Directors Election 2009 Annual Meeting Stockholders Non-controlling Interests Consolidated Financial Statements
Non-small Cell Lung Cancer Non-transferability
Notes Payable Notes Receivable
Notes Receivable Employees Notice Grant
Now Therefore Number Etc
Number Restricted Share Units Granted Unit Plan Number Rsus
Number Shares Common Stock Available Restricted Share Unit Off-balance Sheet Arrangements
Oncothyreon Oncothyreon Inc
Oncothyreon Inc Annual Report Form 2008 Table Contents Operating Leases
Operating Results Affected Currency Exchange Rate Fluctuations Option
Option Exercises Stock Vested Optionee
Other Other Fees
Other Information Other Matters
Overview Part
Participant Participation
Patents Proprietary Information Pending Accounting Pronouncements
Person Plan
Plant Equipment Depreciation Policy Audit Committee Pre-approval Fees
Post-approval Requirements Power Attorney
Preferred Stock Principal Elements Executive Compensation
Product Candidates Never Achieve Market Acceptance Even Obtain Product Candidates Overview
Products Develop Become Subject Unfavorable Pricing Regulations Party Proposal
Proxy Card Revocation Px-12
Px-316 Px-478
Px-866 Rao Koganty
Ratify Selection Deloitte Touche Llp Independent Registered Chartered Recent Accounting Pronouncements
Registrants Telephone Number Including Area Code Registrants Telephone Number Including Area Code 425 450-0370
Registration Rights Reimbursement
Release Date Rely Parties Conduct Clinical Trials Not Perform Contractually
Remediation Report Independent Registered Chartered Accountants
Report Independent Registered Public Accounting Firm Required Redeem Shares Class Preferred Stock Financial Condition
Research Development Research Development Costs
Research Development Manufacturing Research Development Manufacturing Expense
Research Programs Vaccine Technology Restricted Share Unit Plan
Retirement Revenue
Revenue Recognition Right Restricted Share Units Event Death Retirement Resignation
Right Rsus Event Change Control Right Rsus Event Death Retirement Resignation
Robert Kirkman Role Compensation Committee
Royalties Rsu
Rsu Share Rsu Shares Subject Plan
Rsus Rsus Not Shares
Seattle Washington Securities Authorized Issuance Equity Compensation Plans
Service Provider Severance
Severance Termination Protection Share Option Plan
Share Options Share Reserve
Shares Shares Outstanding Quorum
Short-term Investments Signatures
Small Molecule Drugs Solicitation Proxies
Specified Employee Stimuvax
Stimuvax Other Vaccine Product Candidates Based Novel Technologies Stock Performance Graph
Stock Transactions Stock-based Compensation
Stockholder Proposals 2009 Annual Meeting Stockholder Proposals 2010 Annual Meeting
Stockholders Strategic Collaboration Merck Kgaa
Strategy Subsidiary
Summary Restricted Share Unit Plan Table Contents
Tax Fees Termination Service Provider Relationship
Terms Conditions Restricted Share Units Trading Price Common Stock Volatile
Transferability Unable Enter Collaborations Partners Perform Sales Marketing Functions
Unable Obtain Maintain Enforce Proprietary Rights Not Able United States
United States Government Regulation Unregistered Sale Equity Securities
Vaccine Products Variable Cash Compensation Incentive Bonuses
Vote Vote Required Board Directors Recommendation
Voting Shares Warrant Liability
Weighting Compensation Elements Whereas
Withholding Tax Witness Whereof
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki